Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes

IMPORTANCE: Additional treatments are needed for heart failure with reduced ejection fraction (HFrEF). Sodium-glucose cotransporter 2 (SGLT2) inhibitors may be an effective treatment for patients with HFrEF, even those without diabetes. OBJECTIVE: To evaluate the effects of dapagliflozin in patients...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JAMA
Autors principals: Petrie, Mark C., Verma, Subodh, Docherty, Kieran F., Inzucchi, Silvio E., Anand, Inder, Bělohlávek, Jan, Böhm, Michael, Chiang, Chern-En, Chopra, Vijay K., de Boer, Rudolf A., Desai, Akshay S., Diez, Mirta, Drozdz, Jaroslaw, Dukát, Andre, Ge, Junbo, Howlett, Jonathan, Katova, Tzvetana, Kitakaze, Masafumi, Ljungman, Charlotta E. A., Merkely, Béla, Nicolau, Jose C., O'Meara, Eileen, Vinh, Pham Nguyen, Schou, Morten, Tereshchenko, Sergey, Køber, Lars, Kosiborod, Mikhail N., Langkilde, Anna Maria, Martinez, Felipe A., Ponikowski, Piotr, Sabatine, Marc S., Sjöstrand, Mikaela, Solomon, Scott D., Johanson, Per, Greasley, Peter J., Boulton, David, Bengtsson, Olof, Jhund, Pardeep S., McMurray, John J. V.
Format: Artigo
Idioma:Inglês
Publicat: American Medical Association 2020
Matèries:
Original Investigation
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7157181/
https://ncbi.nlm.nih.gov/pubmed/32219386
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2020.1906
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars